10
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T62316 | P-CAB agent 1 | ||
P-CAB agent 1 (compound B19) is a potassium-competitive acid blocker that acts on H+/K+-ATPase (IC50: 60.50 nM). P-CAB agent 1 can be used in the study of acid-related diseases (ARDs). | |||
T72897 | P-CAB agent 2 | ||
P-CAB Agent 2 is a potent, orally active potassium-competitive acid blocker (P-CAB) and gastric acid secretion inhibitor that effectively inhibits H+/K+-ATPase activity, showing an IC50 value of <100 nM. It also demonstr... | |||
T72181 | P-CAB agent 2 hydrochloride | ||
P-CAB agent 2 hydrochloride is a potent, orally active potassium-competitive acid blocker (P-CAB) and gastric acid secretion inhibitor. It effectively inhibits H+/K+-ATPase activity, with an IC50 value of <100 nM, and ta... | |||
T8388 | Vonoprazan | TAK-438 (free base) | Proton pump |
Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis | |||
T21254 | Vonoprazan Fumarate | TAK-438,TAK 438,Vonoprazan Fumurate,TAK438 | Proton pump |
Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19... | |||
T2404 | Vonoprazan fumarate | TAK-438 | ATPase |
Vonoprazan fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase. | |||
T2093 | PF 03716556 | PF-3716556 | ATPase |
PF 03716556 (PF-3716556) , an effective and specific P-CAB (potassium-competitive acid blocker), is utilized for the treatment of gastroesophageal reflux disease. | |||
T2405 | Revaprazan hydrochloride | YH1885 | ATPase , COX , Antibacterial |
Revaprazan hydrochloride (YH1885) is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. | |||
T69613 | Ar-H047108 free base | ||
Ar-H047108 free base is an imidazopyridine potassium competitive acid blocker (P-CAB). This drug may be used to treat early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity. | |||
T61643 | Vonoprazan hydrochloride | ||
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively acts as a potassium-competitive acid blocker (P-CAB) with potent antisecretory activity. It notably inhibits H+,K+-ATPase activity in porcine gastric m... |